Send to:

Choose Destination
See comment in PubMed Commons below
Clin Breast Cancer. 2014 Jun;14(3):205-11. doi: 10.1016/j.clbc.2013.10.018. Epub 2013 Oct 26.

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

Author information

  • 1University of Wisconsin Carbone Cancer Center, Madison, WI; Hematology/Oncology Division, Department of Medicine, University of Wisconsin, Madison, WI. Electronic address:
  • 2University of Wisconsin Carbone Cancer Center, Madison, WI; Hematology/Oncology Division, Department of Medicine, University of Wisconsin, Madison, WI.
  • 3University of Wisconsin Carbone Cancer Center, Madison, WI.
  • 4Bellin Memorial Hospital, Green Bay, WI.
  • 5Columbia St Mary's, Milwaukee, WI.
  • 6Fox Valley Hematology and Oncology, Appleton, WI.
  • 7Aurora Cancer Care, Wauwatosa, WI.
  • 8Gundersen Lutheran Health System, Lacrosse, WI.
  • 9University of Wisconsin Carbone Cancer Center, Madison, WI; Departments of Biostatistics and Medical Informatics and Statistics, University of Wisconsin, Madison, WI.



Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to deliver TC on a dose-dense schedule, with therapy completed within 10 weeks.


We enrolled women with early stage breast cancer on a single-arm phase II study of adjuvant dose-dense TC through a regional oncology network. All women completed primary surgery before accrual, and subsequent therapy with TC was deemed appropriate by the treating physician. Planned treatment was docetaxel 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) every 2 weeks for 4 cycles with subcutaneous pegfilgrastim 6 mg administered 24 to 48 hours after the administration of each chemotherapy cycle.


Of 42 women enrolled, 41 were evaluable using prespecified criteria. Of these, 37 (90.2%) completed therapy within 10 weeks and 34 (83%) completed therapy at 8 weeks without dose modification. Rates of neuropathy were similar to that reported previously. The rate of neutropenic fever was low (2.5%). Rash and plantar-palmar erythrodythesia were common and reached grade 3 in 4 subjects (9.8%).


Dose-dense TC is feasible with tolerability profiles similar to standard TC and a low likelihood of neutropenic fever. This study supports further clinical development of this 8-week adjuvant chemotherapy regimen.

Copyright © 2014 Elsevier Inc. All rights reserved.


Chemotherapy; Febrile neutropenia; Granulocyte-colony stimulating factor; Palmar-plantar erythrodysthesia; Pegfilgrastim

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk